Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating

February 13, 2025

Wednesday, Craig-Hallum initiated coverage on Myriad Genetics (NASDAQ:MYGN) with an optimistic outlook, assigning a Buy rating to the stock along with a price target of $29.00. The firm’s analysis suggests that the current market valuation of Myriad Genetics does not fully reflect the company’s potential, noting that the stock is trading near a 10-year low. InvestingPro data confirms this bearish sentiment, showing the stock trading at $12.62, near its 52-week low of $12.04, after declining 55% over the past six months. Despite recent challenges, three analysts have revised their earnings expectations upward for the upcoming period.

The research firm believes that the market has overly discounted Myriad Genetics’ shares, implying that very little will improve and a lot could deteriorate. Contrary to this sentiment, Craig-Hallum sees the situation from a different perspective. The analysts are confident in the company’s preliminary guidance for the year 2025, considering it not only achievable but possibly even on the conservative side.

According to Craig-Hallum, the stock’s current trade value at just 1.2 times the midpoint of the preliminary 2025 guidance range indicates a lack of market confidence in the company’s forecasted numbers. The firm suggests that if Myriad Genetics manages to deliver results that align with their guidance, it is likely to result in an expansion of the stock’s multiple.

The coverage initiation and the positive rating come at a time when Myriad Genetics’ stock appears undervalued to Craig-Hallum, presenting what they see as an attractive risk-reward scenario for investors. The firm’s stance is based on the belief that the company’s stock price could see significant appreciation merely by meeting its projected financial targets. With the next earnings report due on March 4, investors can access detailed valuation metrics and eight additional ProTips through InvestingPro‘s comprehensive analysis platform.

Wednesday, Craig-Hallum initiated coverage on Myriad Genetics (NASDAQ:MYGN) with an optimistic outlook, assigning a Buy rating to the stock along with a price target of $29.00. The firm’s analysis suggests that the current market valuation of Myriad Genetics does not fully reflect the company’s potential, noting that the stock is trading near a 10-year low. InvestingPro data confirms this bearish sentiment, showing the stock trading at $12.62, near its 52-week low of $12.04, after declining 55% over the past six months. Despite recent challenges, three analysts have revised their earnings expectations upward for the upcoming period.

The research firm believes that the market has overly discounted Myriad Genetics’ shares, implying that very little will improve and a lot could deteriorate. Contrary to this sentiment, Craig-Hallum sees the situation from a different perspective. The analysts are confident in the company’s preliminary guidance for the year 2025, considering it not only achievable but possibly even on the conservative side.

According to Craig-Hallum, the stock’s current trade value at just 1.2 times the midpoint of the preliminary 2025 guidance range indicates a lack of market confidence in the company’s forecasted numbers. The firm suggests that if Myriad Genetics manages to deliver results that align with their guidance, it is likely to result in an expansion of the stock’s multiple.

The coverage initiation and the positive rating come at a time when Myriad Genetics’ stock appears undervalued to Craig-Hallum, presenting what they see as an attractive risk-reward scenario for investors. The firm’s stance is based on the belief that the company’s stock price could see significant appreciation merely by meeting its projected financial targets. With the next earnings report due on March 4, investors can access detailed valuation metrics and eight additional ProTips through InvestingPro‘s comprehensive analysis platform.